menu
menu
Breast Cancer
The emergence of HER2-low therapies for metastatic breast cancer is a paradigm shift in the traditional binary classification of a patient’s HER2 status, creating a need for practice changes in pathology necessitated by the expansion in how HER2-low breast cancer needs to be classified and treated. During this recorded 2022 ASCP Annual Meeting session, a moderated expert faculty panel discussed evolving and emerging trends in breast cancer classification and reporting across the HER2+ spectrum. They also discussed how pathologists and laboratory professionals can prepare for HER2-low classification, tracking, and reporting. In addition, they reviewed some of the current challenges in HER2 testing and explored opportunities to prepare for the future landscape of HER classification in breast cancer.
Topics: HER2; Breast Cancer
This 60-minute interactive webinar will feature the expertise of a pathologist and an oncologist highlighting important and practice-changing developments related to the use of Ki67 biomarker testing in patients with HR-positive/HER2-negative early breast cancer, such as new clinical data with immediate implications for patient care. Case-based, and with expert perspectives and recommendations, this webinar addresses key educational gaps and controversies related to optimal Ki67 biomarker testing methods, including challenges with standardization, interpreting findings, and potential therapeutic implications for patients with HR-positive/HER2-negative early breast cancer to optimize clinical outcomes.
Topics: Ki67; HER2; Breast Cancer
Originally Broadcast January 25, 2022
This virtual tumor board from ASCP will help you understand the science and emerging evidence around HER2-low breast cancer, as well as changes to practice that will be necessary in preparation for anticipated approvals of HER2-low breast cancer therapies.
Topics: HER2; Breast Cancer
Originally Broadcast February 10, 2022
This virtual tumor board from ASCP will help you understand the latest evidence regarding HER2-low breast cancer, HER2 testing guidelines, the implications for the pathology team as HER2-low therapies emerge, and ways to streamline communications with oncologists and other members of the cancer care team.
Topics: HER2; Breast Cancer
Recorded October 2020
This CME/CMLE-accredited online module is designed to help Pathologists, laboratory professionals, and other members of the cancer care team apply the latest scientific evidence when evaluating HER2 status and be comfortable having an open dialogue surrounding challenging HER2 cases and how treatment is informed by HER2 status. Faculty also present information about how the emerging science around HER2‐low may impact patient care.
Topics: HER2; Breast Cancer
Released April 2020
This one-hour interactive, online CME/CMLE module is designed to help pathologists and laboratory professionals gain a deeper scientific understanding of recent advances in the diagnosis and management of HER2-positive and HER2-low breast cancer.
Topics: HER2; Breast Cancer
Released April 2020
This one-hour interactive, online CME/CMLE module is designed to help pathologists and laboratory professionals review and apply key concepts from the ASCO/CAP 2018 focused update on HER2 testing. The module will include a review of the ASCO/CAP 2018 focused update in HER2 testing in breast cancer, as well as application of the updates through case-based scenarios.
Topics: HER2; Breast Cancer